Adverse reactions or lack of response to medications are important concerns for drug
development programs. However, faithful predictions of drug metabolism and toxicity
are difficult because animal models show only limited translatability to humans.
Furthermore, current in vitro systems, such as hepatic cell lines or
primary human hepatocyte (PHH) 2-dimensional (2D) monolayer cultures, can be used
only for acute toxicity tests because of their immature phenotypes and inherent
instability. Therefore, the migration to novel phenotypically stable models is of
prime importance for the pharmaceutical industry. Novel 3-dimensional (3D) culture
systems have been shown to accurately mimic in vivo hepatic
phenotypes on transcriptomic and proteomic level, but information about their
metabolic stability is lacking. Using a combination of targeted and untargeted
high-resolution mass spectrometry, we found that PHHs in 3D spheroid cultures
remained metabolically stable for multiple weeks, whereas metabolic patterns of PHHs
from the same donors cultured as conventional 2D monolayers rapidly deteriorated.
Furthermore, pharmacokinetic differences between donors were maintained in 3D
spheroid cultures, enabling studies of interindividual variability in drug metabolism
and toxicity. We conclude that the 3D spheroid system is metabolically stable and
constitutes a suitable model for in vitro studies of long-term drug
metabolism and pharmacokinetics.—Vorrink, S. U., Ullah, S., Schmid, S.,
Nandania, J., Velagapudi, V., Beck, O., Ingelman-Sundberg, M., Lauschke, V. M.
Endogenous and xenobiotic metabolic stability of primary human hepatocytes in
long-term 3D spheroid cultures revealed by a combination of targeted and untargeted
metabolomics.